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Recent advances in the ﬁeld of neuromyelitis optica (NMO) research provided convincing evidence that anti-AQP4 antibody
(AQP4-Ab) not only serves as a highly speciﬁc disease marker, but also plays an essential role in the pathogenesis of the disease.
Although it is now widely recognized that AQP4-Ab induces astrocytic necrosis in a complement-dependent manner, additional
triggers are also suspected as a prerequisite for the development of the disease. Unraveling these unresolved aspects of the disease
will provide substantial insight into still controversial issues in the pathogenesis of NMO.
1.Introduction
During the past several years there has been a huge progress
in our understanding of the pathogenesis of neuromyelitis
optica (NMO). The discovery of a disease-speciﬁc autoan-
tibody, anti-aquaporin-4 antibody (AQP4-Ab), in the sera
of patients with NMO has attracted enormous attention of
researchers within the ﬁeld [1, 2]. Among a large number of
reports related to the pathogenesis of NMO, animal studies
haveprovidedsubstantialinsightintothepathogenicmecha-
n i s mo fA Q P 4 - A b[ 3–6]. In this review article, we discuss the
current view of the pathogenic mechanism of NMO based
upon the studies of AQP4-Ab, and further point out the
unresolved issues related to the pathogenesis of NMO.
2. AQP4-Ab is Not Only a Disease Marker but
aPathogenic Autoantibody
Since the identiﬁcation of a highly disease-speciﬁc autoan-
tibody, AQP4-Ab, in the sera of patients with NMO, several
clinical observations suggested the pathogenicity of AQP4-
Ab [1, 2]. It has been widely appreciated that the therapeutic
intervention by plasmapheresis is a beneﬁcial treatment
of patients with NMO [7, 8]. The disease activity is also
reported to correlate with the titer of AQP-Ab in the serum
or the CNS [9–11]. More importantly, the active lesions
of NMO are characterized by the loss of AQP4 and glial
ﬁbrillary acidic protein (GFAP) immunoreactivities (IRs)
[12, 13]. In addition to these clinical observations, the direct
evidence of the pathogenicity of AQP4-Ab was recently
provided by in vitro and in vivo studies. It is reported
from several groups that AQP4-Ab-positive sera induce
necrosisofastrocytesinacomplement-dependentmannerin
vitro [14–16]. Another mechanism of Ab-dependent cellular
cytotoxicity (ADCC) is also suggested in assays using human
astrocytes [17]. Most importantly, we and others have shown
that when rats were preimmunized with myelin basic protein
(MBP) and experimental autoimmune encephalomyelitis
(EAE) was induced, injection of immunoglobulins collected
from patients with NMO can induce strikingly similar
pathological features to NMO in the recipient rats [3–
5]. The active lesions of these models were characterized
by the extensive loss of AQP4 and GFAP-IRs especially
around the blood vessels and meninges where AQP4 is
predominantly expressed [3–5]. The speciﬁc deposition of
activated complement and transferred immunoglobulins at
the sites of astrocytic loss was reminiscent of the NMO
patients’pathology[4,5].Itisnoteworthythat,attheborders
of astrocytic loss in this animal model, more extensive loss
of AQP4-IR compared to GFAP-IRwas observed, supporting
the speciﬁcity of AQP4 as a target in this disease model [5].
The speciﬁcity of AQP4-Ab was also conﬁrmed by either
absorbing AQP4-Ab with AQP4-expressing cells or estab-
lishing monoclonal antibodies [3, 4]. These observations2 Multiple Sclerosis International
together have provided convincing evidence that AQP4-Ab
is pathogenic both in vitro and in vivo and plays a pivotal role
in the pathogenesis of NMO.
3. AstrocyticNecrosisIsInducedbyAQP4-Abin
a Complement-Dependent Manner
Apart from the remarkable loss of astrocytes in NMO,
the active lesions are also characterized by the deposition
of activated complement and immunoglobulins [18]. The
majority of AQP4-Ab produced in the sera of patients with
NMO belongs to IgG1 isotype [19], which are the most
potent immunoglobulin subclass capable of activating com-
plement system. These clinical observations highly suggest
that complement system is another essential factor in the
pathogenesis of NMO. The important role of complement
system during the astrocytic death caused by AQP4-Ab was
also supported by animal studies. The lesions of astrocytic
loss in the recipient rats given immunoglobulins of patients
with NMO were accompanied by remarkable deposition
of activated complement or C5b-9 [4, 5, 20]. Moreover, a
C1 complement inhibitor is also reported to prevent the
pathogenic eﬀect of AQP4-Ab in vivo [6]. Similar inhibitory
eﬀect was also observed with cobra venom factor (CVF) on
astrocytic death in our animal model (unpublished data).
CVF is a widely used reagent that transiently depletes the
active components of complement in vivo. When recipient
rats were pretreated with CVF, the loss of GFAP-positive
cells in the spinal cords was much less observed. In vitro
studies also showed that AQP4-Ab-positive sera are capa-
ble of inducing astrocytic death only in the presence of
complement [14, 15]. Furthermore, the type of astrocytic
death caused by AQP4-Ab was shown to be necrosis induced
by immune complexes of C5b-9 [14]. When rat primary
astrocytes were incubated with AQP4-Ab-positive sera, most
of the dying astrocytes became positive both for Annexin
V and PI, the pattern of staining suggesting the necrotic
process in the target cells. Immunocytochemistry of these
cells showed that there is a deposition of C5b-9 on dying
astrocytes [14]. These observations may partially explain
why the active lesions in NMO are characterized by highly
destructive features of necrosis [18].
4.DoAQP4-Abs Become Pathogenic
Once inthe Brain?
Although the passive transfer models of NMO conﬁrmed
the pathogenicity of AQP4-Ab on astrocytes, it still remains
unclear whether AQP4-Ab is a disease-modifying factor or
a primary initiator of the disease [21]. Since AQP4-Ab
does not penetrate the blood-brain barrier (BBB) under
physiological condition [4], there should be at least the
second trigger to break the integrity of the BBB and let
AQP4-Ab get an access to their target antigen in the CNS.
But is the disruption of the BBB enough for AQP4-Ab
to exert its pathogenicity to full extent? Though there are
some anatomical sites where the BBB is relatively loose and
permeable [22], most of the patients who harbor AQP4-
Ab in their sera do not show any clinical symptoms during
remissions [23]. In addition, there is a report of a case that
showed positivity of AQP4-Ab more than 10 years before
the onset of the disease [24]. Unlike myasthenia gravis,
the most well-characterized autoantibody-mediated disease,
maternal transmission of the disease during pregnancy has
n o tb e e nr e p o r t e di nN M O[ 25]. In vivo studies also suggest
that pathological changes are not reproducible even after
transferring patients’ immunoglobulins to juvenile na¨ ıve
rats where the integrity of BBB is still fragile. Therefore,
the access of AQP4-Ab beyond the BBB is presumably not
suﬃcient to induce the astrocytic cytotoxicity [4]. This
hypothesis might seem to contradict with the recent report
that showed the pathogenic eﬀect of AQP4-Ab after being
directly injected into mouse brains with human complement
[6]. This discrepancy, however, may be explained by the
fact that astrocytes are endowed with various types of
complement-regulatory proteins (CRPs), and these CRPs are
known of being not capable of playing their protective role
against activated complement of diﬀerent species [26, 27].
Since the loss of astrocytes was only observed with human
complement but not with mouse complement in the report,
the interpretation of the results in this disease model should
be carefully made [6]. Taken together, we speculate that the
second trigger besides the leakage of BBB might be required
for AQP4-Ab to become fully pathogenic.
5. Nonspeciﬁc Inﬂammation Potentiates
the Full Pathogenicity of AQP4-Abin
the Absence of T Cells
IftheleakageofBBBisnotsuﬃcientforAQP4-Abtobecome
fully pathogenic, then what other factors are necessary? We
have recently shown that pretreatment of recipient rats with
complete Freund’s adjuvant (CFA) alone is suﬃcient for the
AQP4-Ab transferred in the periphery to induce astrocytic
cytotoxicityinthespinalcords[20].CFAisacommonlyused
reagent to induce various models of autoimmune diseases
[28]. CFA activates innate immune cells and leads to the
release of various types of inﬂammatory cytokines [28]. This
nonspeciﬁcally induced inﬂammation in the periphery not
only disrupts the integrity of the BBB but also activates glial
cells in the CNS [29]. In our CFA model, T cells are scarcely
observed in the lesions [20]. Therefore, at the very ﬁrst
step of the development of NMO, nonspeciﬁc inﬂammation
induced in the periphery is suﬃcient to potentiate the
pathogenicity of AQP4-Ab and T cells are not necessarily
required [20]. It remains to be elucidated whether the
alteration of inﬂammatory status in the periphery or that
in the CNS induced after the injection of CFA is important
to break the tolerance. It may be that complement system
gets excessively activated, rendering astrocytes vulnerable
to the attack from immune complexes. Or alternatively,
expression pattern of CRPs might be altered on astrocytes
after the stimulation with CFA. Another possibility is that
inﬂammatory cytokines produced in the CNS alter the
expression pattern or level of AQP4 on astrocytes [30],Multiple Sclerosis International 3
providing more easily accessible target antigens to AQP4-Ab.
Future studies should address this question by examining the
proﬁle of inﬂammatory cytokines and complement-related
molecules, along with the change in the pattern of AQP4
expression within the CNS.
6. Are T Cells Also Responsible for the
Development ofthe Disease?
Although we have learned through our animal model
that nonspeciﬁc inﬂammation is suﬃcient to induce the
pathogenic eﬀect of AQP4-Ab, it is noteworthy that the
lesions observed in CFA model were much less extensive
comparedtothoseofrecipientratspreimmunized withMBP
(EAE model) [5, 20]. Only with high titer of AQP4-Ab the
loss of astrocytes was observed in CFA model while with
antibodies of lower titer only the ballooning of astrocytes
was observed [20]. Taken into account that the active lesions
of NMO also contain substantial number of T cells, T cells
will also aﬀect the disease activity in NMO [18]. Recent
reports showed that certain amino sequence of AQP4 is
immunogenic to induce AQP4-speciﬁc T cells in several
animal strains [31, 32]. More importantly, it is documented
that patients with NMO harbor activated T cells speciﬁc for
AQP4 in the periphery [33]. It is also reported that there
is an increase in Th1 and Th17 subsets in the periphery
of NMO spectrum disorders [34–36]. These observations
suggest that pathogenic T cells against AQP4 do exist in the
periphery of patients with NMO and might also accelerate
the disease activity once they encounter the target antigen
in the CNS. Whether these T cells provide an initial trigger
before the entry of AQP4-Ab remains to be elucidated. Of
note, it is also reported that patients with NMO harbor the
T cells speciﬁc for other antigens comprising the CNS, such
as MBP and proteolipid protein [21, 33]. Where these T cells
ﬁt in the picture of NMO pathogenesis is hard to conclude.
These T cells are probably induced by well-recognized
phenomena of antigen spreading after tissue destruction
by AQP4-Abs. Although less likely, however, we cannot
exclude the possibility that these T cells are initially activated
at the very ﬁrst stage of the disease and AQP4-targeted
inﬂammation occurs afterwards. Notably, less than 30% of
actively demyelinating lesions show AQP4 loss in NMO [21].
7 .TC ell sandt h eL oc atio no f
the Inﬂammation in NMO
The prototypical presentation of NMO is characterized by
preferential involvement of central gray matter in the spinal
cord and brain stems, where AQP4 is known to be expressed
at high level [22]. Recent clinical reports, however, provide
numerous lines of evidence that nonspeciﬁc cerebral lesions
are not as rare as used to be recognized [37]. The change in
this clinical perception of the disease apparently counteracts
with the notion that AQP4-Ab is the only factor blamed
for inducing inﬂammation in the disease. To give rationale
explanation for this discrepancy, we might need to pay more
attention to the role of T cells in the pathogenesis of NMO.
In addition to AQP4-Ab, T cells might play an important
role in deciding the location of lesions in the CNS. Recently
it is reported from several groups that Th1 cells and Th17
cells, the two major proinﬂammatory T cell subsets, induce
distinctphenotypesofinﬂammationinEAEmodels[38,39].
It is interesting that large number of children who show
positive results of AQP4-Ab present with symptomatic brain
involvement [40]. This might be explained by the hypothesis
that the balance between Th1 and Th17 cells aﬀects the
clinical presentation of the disease. Taking into account
the fact that patients with opticospinal involvement show
increase in the production of IL-17 within the CNS, it might
be that patients present inﬂammation in the spinal cords and
not in the brains when Th17 cells become predominant [41].
The exact clinical phenotype induced by Th1 immunity is
not yet clear (see Figure 1). This hypothesis regarding the
balanceofinﬂammatoryT-cellsubsetsindeﬁningthedisease
location might further be extended to explain why some
proportion of patients with typical NMO presentation turns
out to be negative for AQP4-Ab [37]. The passive transfer
of immunoglobulins collected from these so-called seroneg-
ative NMO patients is reported not to induce astrocytic loss
inananimalmodel[4].Thisraisesthequestionastowhether
the so-called seronegative NMO is truly an autoantibody-
mediated disease or not. Given that some patients with
seronegative NMO respond to plasmapheresis, and others
become seropositive during the disease course, heterogenic
pathogenesis is postulated [42, 43].
8. GranulocyteInvolvementin
the Pathogenesis of NMO
In spite of the huge progress in the mechanism of AQP4-Ab-
related pathology, much less is investigated as to how granu-
locytes recruited in the active lesions of NMO are related to
the disease [18]. The granulocytes are generally considered
to be recruited by components of activated complement,
such as C5a and C3a [17]. Besides the involvement of
complement in our disease model [20], we recently observed
that even in the absence of T cells there is an increase in the
expression of CINC-1, a functional homolog of human IL-
8, in the spinal cords of recipient rats (unpublished data).
Considering the fact that increase of IL-8 production is
reported in the spinal cord of patients with opticospinal
manifestation [41], IL-8 produced by astrocytes might be
another essential factor attracting granulocytes in the lesions
[44, 45]. To what extent these recruited granulocytes are
involved in the pathogenesis of NMO still remains to be
elucidated. In vitro studies did not conﬁrm the pathogenic
eﬀect of activated granulocytes on astrocytes even after they
showed degranulation [17]. More detailed studies in vivo
should elucidate whether granulocytes are actively involved
in the formation of pathology in NMO.
9. Conclusions
Recent progress of animal studies has provided substan-
tial insight into our knowledge of NMO pathogenesis.4 Multiple Sclerosis International
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Figure 1: Speculative model of AQP4-Ab-positive NMO is shown in a chronological manner. At the very ﬁrst stage of the disease course,
break of tolerance against AQP4 leads to production of AQP4-Ab in the periphery without manifesting any symptoms. What causes the
compromise of the tolerance is not yet elucidated. Molecular mimicry of AQP4 to certain microbes is one of the possibilities. Onset of
the disease might be triggered by either nonspeciﬁc inﬂammation caused by infections or activation of CNS antigen-speciﬁc T cells. These
stimuli will not only induce the leakage of the BBB, but also alter the inﬂammatory status both in the periphery and within the CNS. Once
the disease develops, the location of the lesions may be determined by the types of T cells inﬁltrating within the CNS. The presence of
AQP4-Ab will further modulate the disease phenotype and produce characteristic lesions of NMO spectrum disorders.
Non-pathogenic recombinant monoclonal anti-AQP4 Ab,
called “aquaporumab,” was recently shown to dramatically
reduce NMO-like lesions in an ex vivo spinal cord slice
model [46]. Although there is no doubt that AQP4-Ab plays
a pivotal role in the development of the disease, AQP4-
Ab alone cannot explain the whole spectrum of the disease
manifestations. The absence of pathological changes in the
peripheral organs expressing AQP4 despite the rapid access
of AQP4-Ab supports this hypothesis [47]. The correlation
ofserumAQP4-Abtiterandthepatients’disabilityorrelapse
rates was also challenged in recent reports [21, 48]. We
suspect that there should be additional triggers to potentiate
the pathogenicity of AQP4-Ab to its full extent. Among the
additional triggers to be considered, inﬂammatory T-cell
subsets should be paid extra attention. Unraveling the exact
role of T cells along with that of recruited granulocytes will
provide deeper understating of the disease mechanism of
patients with NMO spectrum disorders.
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